에 대한 최신 뉴스 Genprex (NASDAQ:GNPX) 주식

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.

독점: 벤징가 프로에서 10월 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, DJT 순위는?

Genprex Inc

CureVac N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small cell lung cancer (sqNSCLC). CVHNLC is CureVac's investigational mRNA-based precision immunotherapy consisting of two different mRNA constructs encoding eight tumor-associated antigens (TAAs) with prevalence across sqNSCLC patients. Encoded antigens include a novel class of TAAs that have not been previously tested in cancer immunotherapy trials.
The phase 1, dose-finding, open-label study will assess the safety and tolerability of CVHNLC plus pembrolizumab in patients with advanced sqNSCLC. The study comprises a dose-escalation part (Part A) of first-line maintenance treatment after either chemotherapy combined with pembrolizumab or pembrolizumab monotherapy. This is followed by an optional dose expansion part (Part B) in which CVHNLC is tested in combination with first-line chemotherapy and pembrolizumab.

Government

News

Regulations

CVAC

MRNA

CureVac Gets FDA Green Light for Lung Cancer Trial With mRNA-Based Immunotherapy

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower on continued weakness following President Trump's recent tariff announcements, which have caused global trade war concerns.

Wallbox Celebrates 100K EV Chargers Made In Arlington; Commits To Long-Term U.S. Electrification Push

enCore Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EU#NASDAQ">EU</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/EU#TSXV">EU</a>) (the "Company" or "enCore"), announced today the results of the most successful month at the Alta Mesa In-Situ Recovery Uranium Central Processing Plant ("CPP") since commencing operations in June 2024. Following previously announced improvements to operations (see <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4399711-1&amp;h=2814273370&amp;u=https%3A%2F%2Fencoreuranium.com%2Fnews%2Fencore-energy-expands-uranium-extraction-capacity-at-alta-mesa-accelerated-wellfield-development-underway%2F&amp;a=EU+NR+dated+March+13%2C+2025">EU NR dated March 13, 2025</a>) with the goal of expanding uranium extraction, decreasing unnecessary costs and increasing efficiency, the Company captured 50,000 pounds of uranium ("U3O8") in the last 26 days in March 2025.&nbsp; With a healthy treasury including unencumbered cash, inventory and marketable securities of ~$40 million USD, the Company continues to improve Alta Mesa CPP operations and the wellfield development program, which is now on track to meet 2025 contract projections. The Company also announced the appointment of Rob Willette, Acting Chief Executive Officer ("A/CEO"), to the Board of Directors and the promotion of Daniel Calderon to Director of Texas Operations. &nbsp;Mr. Willette will hold the Board seat dedicated to the Chief Executive Officer until such time a permanent appointment is made.
 &nbsp;

TSXV:EU

enCore Energy Boosts Production, Appoints Acting CEO Rob Willette to Board Amid Strong Cash Reserves, Hits Uranium Output Milestone With 50,000 Pounds Captured in March

cbdMD initiated this process in March 2021, with the submission of a comprehensive dossier detailing the ingredient's identity, quality, stability, hemp sourcing, extraction controls, labeling, testing requirements, usage instructions, and extensive safety data. In February 2022, cbdMD became the first U.S. brand to receive dossier validation. Since then, cbdMD has worked closely with the FSA, actively addressing inquiries to expedite the regulatory review process.

Health Care

General

YCBD

Cbdmd Announces That Food Dossier Has Advanced To The Last Phase Of Regulatory Assessment With The UK Food Standards Agency, Nearing Final Approval

EON Resources Inc. (NYSE:<a href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) ("EON" or the "Company") is an independent upstream energy company with oil and gas properties in the Permian Basin. Given the current volatility in the market, the Company's contractual hedging program mitigates the negative impact of reduced oil price risk through the end of CY 2025.
Approximately 70% of the Company's oil production is contractually hedged.
Hedge prices the Company receives are from $70.10 to $70.50 per barrel.
The hedges are established and fixed in volume and price for the next 9 months.
"EON has a very responsible hedging program designed to protect the Company from volatile swings in oil prices as we have witnessed this week apparently driven by the expected increase in oil production by Saudi Arabia," said Mitchell B. Trotter, CFO of EON. "While we do not believe that the current oil price volatility will last for an extended period of time, our hedging program mitigates a negative impact to our financial results."

EONR

EON Resources Locks In Oil Prices at $70+ Through 2025 to Guard Against Market Volatility

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $15 to $16.

Price Target

Analyst Ratings

ANGO

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $16

<a href="https://www.globenewswire.com/Tracker?data=Yw-TWCZN9-grHtHI6xQ1MISsc5A_cnAd6iOP9HS2de_E9bO6kmRPpQ7-DdhCIp1XU_MLP8EPDO09LPQydV9zw0TvgUE4ojq7agmELTp5-SL1MHzrzstoyetmyPIknCr7">Plymouth Industrial REIT, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) (the "Company" or "Plymouth") provided an activity update for the first quarter of 2025. The Company also announced details for its first quarter earnings conference call and webcast to be held on May 2, 2025.
Jeff Witherell, Chief Executive Officer and Co-Founder of Plymouth, noted, "Our strong leasing activity in the first quarter underscores the continued demand for well-located, functional industrial space across our markets. Additionally, our acquisition activity remains disciplined and strategic, as we continue to expand our footprint in key logistics hubs with assets that we expect will offer immediate cash flow and long-term value creation."
Leasing Activity Leases commencing during the first quarter ended March 31, 2025, all of which have terms of at least six months, totaled an aggregate of 2,437,267 square feet. These leases included 1,540,756 square feet of renewal leases and 896,511 square feet of new leases. Excluding the effect of the previously announced executed two-year lease at our 769,500-square-foot Class A building in St. Louis (the "St. Louis lease") that commenced on January 15, 2025, rental rates under these leases reflect a 16.2% increase on a cash basis with renewal leases reflecting a 15.0% increase on a cash basis and new leases reflecting a 22.1% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 9.6% on a cash basis and new leases would have increased 0.9% on a cash basis.
Same store occupancy at March 31, 2025, was 94.7%.&nbsp;&nbsp; Total portfolio occupancy at March 31, 2025, was 94.3% which reflects changes from last quarter including a 210-basis-point positive impact from the St. Louis lease, a 45-basis-point positive impact from leasing in in Cleveland, a 15-basis-point positive impact from acquisitions in Cincinnati and Atlanta markets and a net 70-basis-point negative impact from other leasing activity in the quarter.
Executed leases that will commence during 2025, all of which have terms of at least six months, totaled an aggregate of 4,652,684 square feet. These leases, which represent 56.3% of total 2025 expirations, include 3,731,230 square feet of renewal leases (30.0% of these renewal leases were associated with contractual renewals; there only remains a potential of 120,641 square feet of contractual renewals left in 2025) and 921,454 square feet of new leases, of which 740,487 square feet was vacant at the start of 2025. Excluding the effect of the St. Louis lease, rental rates under these leases reflect a 21.8% increase on a cash basis with renewal leases reflecting a 14.7% increase in rental rates on a cash basis and new leases reflecting a 15.3% increase on a cash basis. Including the St. Louis lease, the overall rental rates would have increased 12.1% on a cash basis and new leases would have increased 1.7% on a cash basis.
Acquisition Activity During the first quarter of 2025, Plymouth closed on the acquisition of six industrial buildings totaling 801,161 square feet for a total of $65.1 million and a weighted average initial estimated net operating income ("NOI") yield of 6.8%. Taken together, these 100% leased properties feature a weighted average remaining lease term of 4.4 years. The first quarter activity comprises the following:
<ul>
<li>263,000 square foot industrial building in Cincinnati, Ohio for $23.3 million and an initial estimated NOI yield of 6.7%.</li>
<li>Madison International's 98% joint venture interest in a 297,583 square-foot warehouse facility in Atlanta, Georgia with 100% occupancy for $23.9 million and an initial estimated NOI yield of 6.8%.</li>
<li>The second tranche of the previously announced Cincinnati small bay industrial portfolio consisting of four buildings totaling 240,578 square feet for $17.9 million and representing an estimated NOI yield of 7.0%. &nbsp;</li>
</ul>
Market Portrait Series&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We issued our second Market Portrait with Avison Young highlighting the Memphis industrial market - America's Distribution Center. The Portrait can be found on our corporate website under <a href="https://www.globenewswire.com/Tracker?data=WQ1381YMiTO9gZWqd6tj-ZMNvBYqYE254AygMFMeZN-NmRG6lwAoC9wkc5l3i0enOvFVcIPhVSa3mZAMfWPTGJ-SH_EgQtJUEfOrT84QgHfbXvBabSov5t2KEBwWZyhP5rDZEB_m8nKSLeJgBwdHyw==">Portfolio / Portfolio Map / Memphis</a>.
Known as "America's Distribution Center," Memphis' freight transportation infrastructure connects companies to nearly every major national and international market. Home to the FedEx World SuperHub, Memphis offers local companies an advantage as the cutoff time to drop off packages for next day delivery is later than counterparts in other U.S. cities. The market is served by five Class 1 railroads and is a key market where the eastern railroads CSX and NS can interconnect with western railroads BNSF and UP. In addition, Canadian National offers a key connection from the Gulf Coast to Canada via Memphis. The Memphis region is serviced by six interstate highways, the most significant being I-55 connecting Chicago to New Orleans and I-40 connecting California to North Carolina.
As of December 31, 2024, Memphis was our largest wholly-owned single market position with 63 buildings across approximately 6.4 million square feet.

PLYM

Plymouth REIT Signs Over 2.4M Square Feet in Q1 Leases, Expands Footprint With $65M in New Property Deals, Boosts Occupancy in Key Logistics Hubs

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Biotech

TNXP

Tonix Pharmaceuticals Presented Data And Analyses Of TNX-102 SL Treatment Effects On Fibromyalgia At The American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

BRKR

Bruker Launches 1.3 GHz High-Resolution Nuclear Magnetic Resonance System

Needham analyst Bernie McTernan reiterates DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Buy and maintains $65 price target.

Reiteration

DKNG

Needham Reiterates Buy on DraftKings, Maintains $65 Price Target

Bruker Launches Fourier 80 Multinuclear Benchtop FT-NMR Spectrometer To Enable  X-Nucleus Observations And various 2D Experiments

ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA's strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
"ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States," said Adam Grossman, President and Chief Executive Officer of ADMA. "The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The Company's vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution. Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance, but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base."

ADMA

ADMA Highlights US-Based Supply Chain as Key Advantage in Tariff Era

Moderna Will Present Research Across Multiple Infectious Disease Areas, Including COVID-19, Influenza, Respiratory Syncytial Virus, Cytomegalovirus, Norovirus, And mpox, At The European Society Of Clinical Microbiology And Infectious Diseases

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy and maintains $80 price target.

BEAM

HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

<ul>
<li>Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days.</li>
<li>Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist.</li>
<li>iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026.</li>
</ul>

IBIO

iBio's Non-GLP Non-human Primate Pharmacokinetics Study Suggests IBIO-600, Anti-myostatin Antibody Designed For Subcutaneous Administration, Could Provide A Significantly Extended Half-life In Humans And A Weight Loss Treatment Option While Preserving And Promoting Muscle Growth

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>, TASE: GILT))), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat Defense was awarded a contract to provide ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed worldwide in support of U.S. Department of Defense (DoD) customers. The contract includes a base program with options to extend up to five years, totaling up to $23 million.
Under the agreement, Gilat Defense will deliver critical program management, field services, and technical support, ensuring operational readiness and continued reliability of these vital communication assets.

GILT

Gilat Wins $23M Deal to Support Satellite Terminals for US Defense Department

<ul>
<li>Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks.</li>
<li>19.2% placebo-adjusted BMI reduction achieved in adult patients 18 years old and older (n=49) at 52 weeks.</li>
<li>20.2% placebo-adjusted BMI reduction achieved in patients younger than 18 years old (n=71) at 52 weeks.</li>
<li>Regulatory submissions in the U.S. and EU anticipated to be completed in the third quarter of 2025.</li>
</ul>

RYTM

Rhythm Pharmaceuticals' Phase 3 TRANSCEND Trial Of Setmelanotide For Acquired Hypothalamic Obesity, Met Its Primary Endpoint With Statistically Significant And Highly Clinically Meaningful Reduction In Body Mass Index In Adult And Pediatric Patients Versus Placebo

United Homes Posts 22.9% Decrease In Q1 Net New Orders

Republic Airways Holdings Inc. and Mesa Air Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) today announced that they have entered into a definitive agreement to merge and create a leading publicly-traded regional airline company in an all-stock transaction. Upon closing, the combined company will be renamed Republic Airways Holdings Inc. and is expected to remain NASDAQ-listed under the new ticker symbol "RJET".

MESA

Republic Airways and Mesa Air Merge in All-Stock Deal to Create New Nasdaq-Listed Airline

Press Releases

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Small Cap

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Contracts

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex to Participate at BIO Europe Spring 2025

CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

BETRF

CSDX

CSE:BETR

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Ensysce Biosciences

Entero Therapeutics

Galecto

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Organovo Holdings

Palisade Bio

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Synaptogenix

Tharimmune

Theriva Biologics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

HC Wainwright & Co.

Dawson James

Screenshot 2023-07-10 at 5.56.06 PM

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

매 거래일마다 수백 개의 헤드라인과 보도자료가 벤징가 프로에 올라와, 트레이더들이 전체 시장과 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1" target="_blank" rel="noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 10월에 벤징가 프로에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 실적은 11월 1일 기준이며 배당금은 포함되지 않았다.
1. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
&#8211; 현재 가격: $248.98 
&#8211; 52주 가격 범위: $138.80 ~ $273.54 
&#8211; 연초 대비 수익률: +0.2% 
&#8211; <a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월</a>/<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noopener" data-google-interstitial="false">9월</a> 순위: 1위/3위/3위
2. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
&#8211; 현재 가격: $135.37 
&#8211; 52주 가격 범위: $44.90 ~ $144.42 
&#8211; 연초 대비 수익률: +181.0% 
&#8211; 7월/8월/9월 순위: 2위/1위/1위
3. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
&#8211; 현재 가격: $30.56 
&#8211; 52주 가격 범위: $11.75 ~ $79.38 
&#8211; 연초 대비 수익률: +75.7% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/20위
4. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
&#8211; 현재 가격: $571.04 
&#8211; 52주 가격 범위: $426.56 ~ $586.12 
&#8211; 연초 대비 수익률: +20.8% 
&#8211; 7월/8월/9월 순위: 3위/2위/2위
5. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
&#8211; 현재 가격: $26.05 
&#8211; 52주 가격 범위: $24.92 ~ $122.90 
&#8211; 연초 대비 수익률: -8.8% 
&#8211; 7월/8월/9월 순위: 19위/4위/7위
6. 브라이트 마인즈 바이오사이언시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>)
&#8211; 현재 가격: $48.18 
&#8211; 52주 가격 범위: $0.93 ~ $79.02 
&#8211; 연초 대비 수익률: +2,518.5% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
7. 어드밴스드 마이크로 디바이시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
&#8211; 현재 가격: $141.86 
&#8211; 52주 가격 범위: $110.22 ~ $227.30 
&#8211; 연초 대비 수익률: +2.4% 
&#8211; 7월/8월/9월 순위: 14위/8위/상위 20위 미포함
8. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
&#8211; 현재 가격: $222.91 
&#8211; 52주 가격 범위: $164.08 ~ $237.49 
&#8211; 연초 대비 수익률: +20.1% 
&#8211; 7월/8월/9월 순위: 7위/6위/4위
9. 테보젠 바이오 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>)
&#8211; 현재 가격: $2.37 
&#8211; 52주 가격 범위: $0.26 ~ $21.09 
&#8211; 연초 대비 수익률: -78.7% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
10. 오클로 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)
&#8211; 현재 가격: $21.67 
&#8211; 52주 가격 범위: $5.35 ~ $28.12 
&#8211; 연초 대비 수익률: +104.4% 
&#8211; 7월/8월/9월 순위: 상위 20위 미포함/상위 20위 미포함/상위 20위 미포함
주목할 만한 주식들:다음 주식들은 2024년 10월 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>에서 11위에서 20위까지 가장 많이 검색된 종목들이다.
11. 아마존닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
12. 마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)
13. 메타 플랫폼 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
14. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
15. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
16. 마이크로스트레티지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)
17. 젠프렉스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>)
18. 소파이 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
19. 보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)
20. 테라울프 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)
중요한 이유 (Why It&#8217;s Important): 테슬라는 사이트에서 가장 많이 검색되는 티커 중 하나로, 10월에 벤징가 프로에서 가장 많이 검색된 종목이 되었다. 주가는 지난 두 달 동안 3위를 기록했으나, 7월에는 1위를 차지한 바 있다.
엔비디아는 10월에 2위로 순위가 하락했으며, 지난 두 달 동안 1위를 기록했다. 이 기술 대기업은 잠시 동안 애플과 마이크로소프트를 제치고 <a href="https://www.benzinga.com/markets/equities/24/10/41551461/nvidia-overtakes-apple-as-worlds-most-valuable-company-again" target="_blank" rel="noopener" data-google-interstitial="false">세계에서 가장 가치 있는 회사</a>로 등극하기도 했다.
10월의 가장 큰 변동 종목 중 하나는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립한 미디어 회사이다. 주식은 선거일을 앞두고 최근 몇 주 동안 급등했다. 트럼프의 2024년 대통령 선거 승리 확률은 <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong" target="_blank" rel="noopener" data-google-interstitial="false">예측 시장</a>과 스포츠 베팅 앱에서 상승했다.
이 주식은 또한 높은 공매도 비율을 가진 <a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">공매도 압박 종목(</a><a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">short-squeeze</a><a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-" target="_blank" rel="noopener" data-google-interstitial="false">)</a>으로 주목받았다. 트럼프가 2024년 선거에서 승리할 경우 주가는 급등할 수 있다. 반대로, 트럼프가 선거에서 패할 경우 주가는 크게 하락할 수 있다.
트럼프 미디어 앤 테크놀로지 그룹은 11월에도 벤징가 프로에서 가장 많이 검색된 티커 중 하나가 될 가능성이 높으며, 선거일은 11월 5일이다. 이 주식은 9월에 20위에 올랐고, 8월이나 7월에는 상위 20위에 포함되지 않았다.
SPDR S&amp;P 500 ETF Trust는 지난 두 달간 2위에서 4위로 하락했으며, 이는 위에 언급된 주식들에 대한 관심 증가 때문일 가능성이 크고, S&amp;P 500 시장 지수에 대한 관심 감소 때문은 아니다. 또한, 나스닥 100 지수를 추적하는 Invesco QQQ Trust ETF는 6위에서 15위로 하락하여, ETF와 시장 지수에 대한 관심이 줄어들었을 가능성을 나타낸다.
상위 10위에 새롭게 진입한 주식은 브라이트 마인즈 바이오사이언시스, 테보젠 바이오 및 오클로로, 이들은 이전에 어떤 달에도 상위 20위에 포함된 적이 없다. 테보젠의 주식은 2024년에 크게 하락했으며, 브라이트 마인즈와 오클로는 각각 2024년에 100% 이상 상승했다.
AMD도 7위로 상위 10위에 재진입했으며, 이는 9월에 상위 20위에서 탈락한 후의 일이다. 이 주식은 2024년 동안 매달 상위 10위와 상위 20위 사이에서 계속 오르락내리락하고 있다.
상위 10위에서 Invesco QQQ와 함께 탈락한 주식은 휠러 리얼 에스테이트 인베스트먼트 트러스트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>), 갈메드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>), 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) 및 인튜이티브 머신스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)이다.
전반적으로 10월 한 달 동안 9월의 상위 10위 주식 중 5개가 동일하게 유지되었고, 9월의 상위 20위 주식 중 8개가 동일하게 유지되었다.
다음 기사:
<ul class="block core-block">
<li><a href="https://www.benzinga.com/general/education/24/10/41665149/these-10-stocks-were-s-p-500s-top-performers-in-bidens-first-year-could-the-trend-continue-if-h" target="_blank" rel="noopener" data-google-interstitial="false">These 10 Stocks Were S&amp;P 500's Top Performers In Biden's First Year: Could Trend Continue If Harris Wins 2024 Election?</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Genprex

뉴스

에 대한 최신 뉴스 Genprex (NASDAQ:GNPX) 주식

월요일, 11월 04, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌